Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.30 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9532794 | 0.75 | OPRM1 (0.36) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL17037499 | 0.74 | CRBN (0.37) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL130746 | 0.74 | — | — | |
| SCHEMBL12727654 | 0.74 | MEN1 (0.34) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| SCHEMBL19419770 | 0.73 | TRIM24 (0.31) | TRIM24TRIM33 | |
| SCHEMBL8023943 | 0.72 | HSD11B1 (0.44) | OPRM1OPRD1OPRK1OPRL1MEN1 | |
| SCHEMBL14747670 | 0.72 | MEN1 (0.33) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| SCHEMBL607485 | 0.70 | — | — | |
| SCHEMBL22690012 | 0.70 | TRIM24 (0.36) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| SCHEMBL28982664 | 0.70 | MEN1 (0.32) | MEN1CYP2C9KMT2ATRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210046070-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANDOS BIOPHARMA, INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-10906033-B2 | Synthesis and application of chiral substituted polyvinylpyrrolidinones | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200306737-A1 | SYNTHESIS AND APPLICATION OF CHIRAL SUBSTITUTED POLYVINYLPYRROLIDINONES | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION | 2020-10-01 | — | — | US | disclosed |
| WO-2017172763-A1 | SYNTHESIS AND APPLICATION OF CHIRAL SUBSTITUTED POLYVINYLPYRROLIDINONES | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2017-10-05 | — | — | WO | disclosed |
| US-9487504-B2 | Imidazolyl analogs as syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9376418-B2 | Substituted pyridine spleen tyrosine kinase (SYK) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-06-28 | — | — | US | disclosed |
| EP-2582692-B1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-22 | — | — | EP | disclosed |
| EP-2582692-B1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-22 | — | — | EP | disclosed |
| US-20150175575-A1 | IMIDAZOLYL ANALOGS AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2015-06-25 | — | — | US | disclosed |
| US-9062048-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-8518969-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-27 | — | — | US | disclosed |
| US-8518969-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-27 | — | — | US | disclosed |
| US-8518969-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-27 | — | — | US | disclosed |
| EP-2582692-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | Janssen Pharmaceutica, N.V. (BE) | 2013-04-24 | — | — | EP | disclosed |
| WO-2011159854-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011159854-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-22 | — | — | WO | disclosed |
| US-20110312936-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTAICA N.V. (BE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312936-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTAICA N.V. (BE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312936-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTAICA N.V. (BE) | 2011-12-22 | — | — | US | disclosed |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210046070-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANCL2, CBS, LCP2 | OPRM1 4522/4885OPRD1 4452/4885OPRK1 4698/4885 |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | JAK1, JAK2, JAK3 | OPRM1 4370/4885OPRD1 4500/4885OPRK1 3125/4885 |
| US-20110312936-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | OPRM1 448/4885OPRD1 117/4885OPRK1 94/4885 |
| US-20200306737-A1 | SYNTHESIS AND APPLICATION OF CHIRAL SUBSTITUTED POLYVINYLPYRROLIDINONES | POLRMT, CNBP, DHPS | OPRM1 460/4885OPRD1 321/4885OPRK1 114/4885 |
| US-20150175575-A1 | IMIDAZOLYL ANALOGS AS SYK INHIBITORS | SYK, BTK, LCK | OPRM1 4544/4885OPRD1 4045/4885OPRK1 2417/4885 |
| US-10906033-B2 | Synthesis and application of chiral substituted polyvinylpyrrolidinones | POLRMT, CNBP, DHPS | OPRM1 460/4885OPRD1 321/4885OPRK1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.